Subcutaneous ICD therapy results in a similar quality of life compared with transvenous ICD therapy during both short- and long-term follow-up

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Boston Scientific Medical device company St. Paul, Minnesota, USA INTRODUCTION: The PRAETORIAN trial showed that the subcutaneous implantable cardioverter defibrillator (S-ICD) is noninfer...

Descripción completa

Detalles Bibliográficos
Autores principales: De Veld, J A, Delnoy, P P H M, Olde Nordkamp, L R A, Kuschyk, J, Bonnemeier, H, Bijsterveld, N R, Boersma, L V A, El Chami, M F, Smeding, L, Weger, A, Richter, S, Betts, T R, Wright, D J, Wilde, A A M, Knops, R E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
14.2 - Implantable Cardioverter-Defibrillator (ICD)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207227/
http://dx.doi.org/10.1093/europace/euad122.427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207227/
http://dx.doi.org/10.1093/europace/euad122.427

Ejemplares similares